Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

istory of hepatitis, alcoholism, or liver cirrhosis may exacerbate underlying hepatic insufficiency. Caution in patients with impaired hepatic function.

Concurrent radiotherapy (given together or <7 days apart): Gemcitabine has radiosensitising activity and significant toxicity may occur, particularly with large volumes of radiotherapy. It is feasible to administer gemcitabine at lower doses than 1,000mg/meter squared with concurrent radiotherapy with predictable toxicity (see SPC).

Sequential radiotherapy (given >7 days apart): Enhanced toxicity has not occurred when gemcitabine was started after the resolution of acute radiation effects or at least one week after radiation. Enhanced toxicity from radiation therapy following gemcitabine exposure has not occurred.

Precautions

Usage in pregnancy or lactation: Avoid in pregnant or breast-feeding women, since safety has not been established. Experimental animal studies have shown reproductive toxicity.

Patients should be cautioned against driving or operating machinery until they are sure they do not become somnolent.

Adverse Reactions

Haematological: Very common: Anaemia, leucopenia, neutropenia, and thrombocytopenia. Common: Febrile neutropenia. Very rare: Thrombocythaemia.

Hepatobiliary: Very common: Elevation of liver transaminases (AST, ALT) and alkaline phosphatase. Common: Increased bilirubin. Very rare: Serious hepatotoxicity, including liver failure and death, in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs. Rare: Increased gamma-glutamyl transferase (GGT).

Gastro-intestinal: Very common: Nausea or vomiting, which require therapy in about 20% of patients and is rarely dose-limiting. Common: Diarrhoea, oral toxicity (mainly soreness and erythema), and constipation.

Renal: Very common: Proteinuria and haematuria, rarely clinically significant. Rare: Haemolytic uraemic syndrome and renal failure of unkno
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. ... comprehensive metagenomic services and data analysis, was the genomic ... ) Phase I/II clinical trial of SER 109, ... recurrent Clostridium difficile infections (CDI). ... Seres Health,s R&D and clinical programs. Such genomic characterization ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/wdq92g/global_and ) has announced the addition of ... Report 2014"  report to their offering.  ... Global and Chinese Acne Medication Industry Report ... on the current state of the global ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... Nov. 3, 2010 Telik, Inc. (Nasdaq: TELK ... $0.09 per share, for the third quarter ended September 30, ... $0.11 per share, for the comparable period in 2009. ... costs and expenses were $4.7 million, compared with $6.2 million in ...
... N.J., Nov. 3, 2010 Regado Biosciences, a privately ... active control agents, announced that Ellen McDonald, MBA, Senior ... at IMPACT 2010 held at the Pennsylvania Convention Center ... at 11:13 a.m. EST on Wednesday, November 10 in ...
Cached Medicine Technology:Telik Announces Third Quarter 2010 Financial Results 2Telik Announces Third Quarter 2010 Financial Results 3Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 2Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 3
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... new diagnostic technique capable of producing three-dimensional, in-depth ... number of women who are recalled for additional ... clinical trial being conducted at Emory University Breast ... annual meeting of the Radiological Society of North ...
... Procedures through the Belly Button: Scar-Free ... ... Nov. 28 Cleveland Clinic urologists recently,performed a series of ... repair), ileal ureter replacement, and psoas hitch uretero-,neocystostomy (for ureteral ...
... Medical Entrepreneurs is Only a Phone Call or ... care entrepreneurs,working outside the traditional health insurance payment ... computer software to make,medical care more accessible and ... the National Center for Policy Analysis (NCPA)., http://www.ncpa.org/pub/st/st305/st305.pdf ...
... Be Presented at 9:00 a.m. ... ... The Trade, Health and Environment,Impact Project, a collaboration of community organizations ... East Yard Communities for Environmental Justice, Center for,Community Action & Environmental ...
... and clinical ... development experience to Celator., PRINCETON, N.J., ... develop combination chemotherapies to,treat different types of cancer, today ... R. Appelbaum, M.D., head of the,University of Washington School ...
... that had the neurological disease, researchers say , WEDNESDAY, ... to a possible treatment for amyotrophic lateral sclerosis (ALS), ... a protein normally found in human cells into mice ... The team found that the treatment delayed symptoms and ...
Cached Medicine News:Health News:'Stereo' mammography takes breast imaging to a new dimension 2Health News:World Firsts by Cleveland Clinic Urologists 2Health News:NCPA Study: Government, Insurers Keep Medicine in Stone Age 2Health News:NCPA Study: Government, Insurers Keep Medicine in Stone Age 3Health News:Los Angeles Port Pollution, Int'l Trade & Goods Movement Conference This Weekend 2Health News:Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals 2Health News:Cell Protein Might Help Treat ALS 2
96-Well PCR Plate Sealing Mat...
Easy to pierce, remove using foil stripper...
Inquire...
... Sealing Foil and Heat Sealing Film each provide ... safe and easy sample storage. In automated procedures ... standard pipette tips. The Heat Sealing Film is ... the plates. Heat Sealing Foil is removed by ...
Medicine Products: